Study of metabolic change produced by chemotherapy in pancreas cancer
Fecha
2024-07-22
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad Rey Juan Carlos
Resumen
Despite its low incidence, pancreatic cancer is responsible for many deaths each year due to
its aggressiveness, late detection, and ease of metastasis. Currently, the best treatment is
complete resection of the tumor followed by the administration of adjuvant chemotherapy.
This project studies the possibility that pancreatic tumor cells can make a metabolic
change after being treated with FOLFIRINOX and gemcitabine with Nab-paclitaxel, the
two types of chemotherapy most used in patients with pancreatic cancer. In particular,
we want to demonstrate that the use of adjuvant chemotherapy favors the metabolic
change when cells use fatty acids as a source of energy, because tumor cells behave more
aggressively in lipid environments.
To this end, 4 pancreatic tumor cell lines (PL-45, MIA PaCa-2, PANC-1 and BxPC-3)
are analyzed under basal conditions to determine the type of metabolism they present
and their dependence, capacity and flexibility to use glucose and fatty acids. as energy
sources. Later, 2 of these cell lines (MIA PaCa-2 and PANC-1) are treated to compare
the differences between the cells in basal conditions and after receiving a stimulus of
FOLFIRINOX, on the one hand, and gemcitabine with Nab-paclitaxel on the other.
Finally, it is proven that the use of these drugs leads to a metabolic reprogramming
that produces a loss of dependence and an increase in flexibility to use energy sources
different from those measured in all the cases studied.
Descripción
Trabajo Fin de Grado leído en la Universidad Rey Juan Carlos en el curso académico 2023/2024. Directores/as: Ana Chocarro Calvo, Javier Martínez Useros